Thiabendazole

Summary

Thiabendazole (CHEMBL625) is an approved small-molecule antinematodal drug (ATC D01AC06); indicated across 1 condition including helminthiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AC06 (+1 more)
• Indications: 1 condition
• Chemistry: 201.25 Da · C10H7N3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL625
Name	Thiabendazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5430
ChEBI	CHEBI:45979
ATC	D01AC06, P02CA02
Molecular formula	C10H7N3S
Molecular weight	201.25
InChIKey	WJCNZQLZVWNLKY-UHFFFAOYSA-N

SMILES: C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3

IUPAC name: 4-(1H-benzimidazol-2-yl)-1,3-thiazole

ChEBI definition: A member of the class of benzimidazoles carrying a 1,3-thiazol-4-yl substituent at position 2. A mainly post-harvest fungicide used to control a wide range of diseases including Aspergillus, Botrytis, Cladosporium and Fusarium.

Pharmacological roles (ChEBI): antinematodal drug, antifungal agrochemical.

Also known as: E233, Lombristop, Mintezol, Minzolum, MK-360, Nemapan, NSC-525040, NSC-90507, Omnizole, Pitrizet, Thiabendazole, Thiabenzole

Patent coverage: 21,001 distinct patent families (58,476 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 58,087 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 19 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Lysine-specific demethylase 4E, Survival motor neuron protein, NPC intracellular cholesterol transporter 1, Ras-related protein Rab-9A, Protein deacetylase HDAC6, Peptidyl-prolyl cis-trans isomerase FKBP1A, Thyrotropin receptor, Methionine aminopeptidase 1, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 17 potent at pChembl ≥ 5 of 33 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP1A2	6.9	AC50	125.9	nM	CHEMBL_ACT_6020577
HDAC6	6.44	IC50	362.9	nM	CHEMBL_ACT_23140996
P0AE18	6.33	IC50	472	nM	CHEMBL_ACT_1670272
CYP1A2	6.1	IC50	800	nM	CHEMBL_ACT_7808466
RAB9A	5.6	Potency	2512	nM	CHEMBL_ACT_3873692
HIF1A	5.6	Potency	2512	nM	CHEMBL_ACT_4130633
HIF1A	5.6	Potency	2512	nM	CHEMBL_ACT_4518910
METAP1	5.47	EC50	3400	nM	CHEMBL_ACT_13281619
NPC1	5.45	Potency	3548	nM	CHEMBL_ACT_4693299
ADORA3	5.43	AC50	3731	nM	CHEMBL_ACT_25198957
SMN1	5.2	Potency	6310	nM	CHEMBL_ACT_3905452
CYP2C19	5.1	Potency	7943	nM	CHEMBL_ACT_4006050
CYP2C19	5.1	AC50	7943	nM	CHEMBL_ACT_6017329
SMN1	5.05	Potency	8912	nM	CHEMBL_ACT_3876568
TP53	5	Potency	10000	nM	CHEMBL_ACT_4862668
CYP2D6	5	Potency	10000	nM	CHEMBL_ACT_4969816
CYP2D6	5	AC50	10000	nM	CHEMBL_ACT_6050121

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
helminthiasis	4	MONDO:0004664	EFO:1001342

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).